Physiochemical drug properties associated with in vivo toxicological outcomes. - Test2 - elhamkhani - TriplyDB

Physiochemical drug properties associated with in vivo toxicological outcomes.

Physiochemical drug properties associated with in vivo toxicological outcomes.

http://www.wikidata.org/entity/Q34806480

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury Rational approaches to improving selectivity in drug design Chemical libraries dedicated to protein-protein interactions Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties.Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains Rational methods for the selection of diverse screening compounds Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes Automated design of ligands to polypharmacological profiles.SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data Fundamentals of translational neuroscience in toxicologic pathology: optimizing the value of animal data for human risk assessment.Interpreting physicochemical experimental data sets.Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate.Predicting cytotoxicity from heterogeneous data sources with Bayesian learning.Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Challenges of antibacterial discovery Physicochemical drug properties associated with in vivo toxicological outcomes: a review.Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists.Probing the probes: fitness factors for small molecule tools.Amphiphile regulation of ion channel function by changes in the bilayer spring constant.Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: increasing hit rate via virtual screening methods.A leap into the chemical space of protein-protein interaction inhibitors Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis Focused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space.Structure-based virtual screening for drug discovery: principles, applications and recent advances.pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.FAF-Drugs3: a web server for compound property calculation and chemical library design.Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Improving MM-GB/SA Scoring through the Application of the Variable Dielectric Model.Imbalance in chemical space: How to facilitate the identification of protein-protein interaction inhibitors.Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study.iPPI-DB: an online database of modulators of protein-protein interactions.Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs.GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.Predictive toxicology approaches for small molecule oncology drugs.Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Metabolites: have we MIST out the importance of structure and physicochemistry?Novel γ-secretase modulators: a review of patents from 2008 to 2010.

P2860

Q24273350-CD8685C1-32FD-4DFD-84CC-A335A3C86C29 Q26749054-3CA96473-C167-4AFD-A33F-FEAE5F9A0139 Q26865357-6B02F2E6-F162-4B14-A9A6-345116BE5D24 Q27010681-0B830EC6-6D3C-433B-AA81-D6DEB091461F Q27308002-E9BA6FE8-71FD-4FF9-B7CA-74269412B140 Q27680405-BE046780-9A67-4881-BC61-CAB6D9C18D94 Q28303907-0720FCAA-526D-48C8-9A6C-4FB3679E3A96 Q28728799-1DA96D3D-68E8-45EC-910F-B7C5E073782D Q30539786-AB1CAA25-5E05-4395-A906-77A43B1A65A1 Q30585642-E9F9A2FE-C531-49B3-B262-2A248D80104B Q30869945-D89E55E9-E966-4CF4-92F6-41EF4973D7DB Q30967921-F1FB06FF-F4EC-49AA-BFC3-8D7D04D90555 Q33598794-220E8010-83CF-4B8D-9C50-C5F7CAD58363 Q33598799-AADDD160-A31E-442D-A5F6-B986E2EB5D2E Q33766983-ECDB4695-8899-4D9B-9F28-11A0859D51AA Q33784830-8D6986C0-3766-4D21-A638-46A0458992D9 Q33793074-F210AA61-901A-4EC6-878B-12D27DE3A683 Q33845886-3FC04DD3-2EBA-40F8-901D-A8EBD19ABC85 Q33899493-D871049B-DEF3-4BF7-A660-DC3A1EC9186F Q34001269-2E90A5A5-3295-4144-BD18-0B60D3365C61 Q34100444-F701F81C-CA41-45A7-B812-B4E1C9899204 Q34180451-4BEC70E3-2AC0-4F08-A748-7AC6349046A7 Q34287849-F8A1D057-024F-4DB7-A704-B103AFA1F693 Q34725554-72A64A36-71DA-4CA4-A404-34093C2CD802 Q35158672-F4F6A0A0-2A13-4F6A-AC04-292D405B07EA Q35282223-E4A89D35-2CEC-43CB-BFDF-507F8062163F Q35599192-EAF39B2B-9533-4DD0-933E-50C1B6115148 Q35604907-7FA4A727-0758-49CF-9902-96A4268C52C5 Q35814421-881B2411-9A9C-44AB-A0A7-2649A30C6980 Q35955749-805B8D43-85D5-47D6-8C82-DE5D6F997636 Q35976167-09D5A911-8915-49E1-BB98-48BD6BC95D25 Q36091191-9BB39EF2-2BCD-4A9E-848C-BCAC5A85470E Q36435078-EA67686C-660D-4A85-880E-B2AED93D3DE2 Q36517549-4A61B878-7827-4090-AEAC-7FEAC67F28A4 Q37335823-C469B88D-124E-4E84-A247-D6A1B961F883 Q37449692-D378A1FB-62B8-4F22-8C84-9CE70E90825E Q37675456-EA937360-6E14-44B6-8307-124C550B7166 Q37740151-686438D4-E1DB-40F2-8FB2-DFA973B5699E Q37810225-1FAD7BCA-9290-41F8-8110-A4FCE01385BA Q37828163-E184C8DF-B59A-4509-BAD0-6237D4B4F1BF

P2860

Physiochemical drug properties associated with in vivo toxicological outcomes.

http://www.wikidata.org/entity/Q34806480

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Physiochemical drug properties associated with in vivo toxicological outcomes.

@ast

Physiochemical drug properties associated with in vivo toxicological outcomes.

@en

Physiochemical drug properties associated with in vivo toxicological outcomes.

@nl

type

label

Physiochemical drug properties associated with in vivo toxicological outcomes.

@ast

Physiochemical drug properties associated with in vivo toxicological outcomes.

@en

Physiochemical drug properties associated with in vivo toxicological outcomes.

@nl

prefLabel

Physiochemical drug properties associated with in vivo toxicological outcomes.

@ast

Physiochemical drug properties associated with in vivo toxicological outcomes.

@en

Physiochemical drug properties associated with in vivo toxicological outcomes.

@nl

P1433

Q34806480-2D9BA4BD-916E-4855-970A-A49C569C14CC

P1476

Q34806480-81B77A48-C9DE-4700-9667-D46F5F354AE8

P2093

Q34806480-10AACB47-9235-4E5B-95C0-D2A0ACF283D1

Q34806480-1A511B1E-1959-418D-A3BA-4102777A7D5A

Q34806480-3DBF3A74-BB65-41DE-9BEA-B1141D16AEA7

Q34806480-44FEACCE-8229-46B7-BF6B-CBE7D54EC67C

Q34806480-5511211A-728D-4759-B768-E32080393D84

Q34806480-58E96EDD-6856-46CA-BEAD-08F70D1FB86A

Q34806480-725B7001-6566-4D8B-B5C7-5AFCED4108A8

Q34806480-7935DCED-2050-4DDB-AF5F-B19B0ED5FAA2

Q34806480-8BB8BCD6-4E50-4914-90FC-DCB29C1867F1

Q34806480-91B494D7-1D6B-4BDE-B1AD-4ECB5BDA4E2B

P304

Q34806480-CA0472F0-B6E5-4DDD-825D-F31AF7006C12

P31

Q34806480-9952DC07-D7FC-4ACB-AF58-AF7D462C17D3

P356

Q34806480-3C8031BD-DDF1-4419-AB0E-9260AB954696

P407

Q34806480-D4428DF2-0793-48FA-AE4C-CCDEE918782B

P433

Q34806480-62FF4CB3-0FFE-4A33-95FA-48CBEEB6EECA

P478

Q34806480-CD3DF5C8-BDE0-4C6C-8138-F16C5556FD12

P577

Q34806480-C5C9D033-6611-4EEE-A084-350BD4DEEEE7

P5875

Q34806480-C7A20A51-298D-4035-84C1-2312DBE531F2

P698

Q34806480-4A9739C2-06A7-4F45-834B-E9D527C930E5

P356

J.BMCL.2008.07.071

P1433

Bioorganic & Medicinal Chemistry Letters

P1476

Physiochemical drug properties associated with in vivo toxicological outcomes.

@en

P2093

David A Price

http://www.w3.org/2001/XMLSchema#string

Edmund Ellsworth

http://www.w3.org/2001/XMLSchema#string

Enoch Huang

http://www.w3.org/2001/XMLSchema#string

Gary A Decrescenzo

http://www.w3.org/2001/XMLSchema#string

Jason D Hughes

http://www.w3.org/2001/XMLSchema#string

Jens Loesel

http://www.w3.org/2001/XMLSchema#string

Julian Blagg

http://www.w3.org/2001/XMLSchema#string

Larry Whiteley

http://www.w3.org/2001/XMLSchema#string

Michael E Gibbs

http://www.w3.org/2001/XMLSchema#string

Nigel Greene

http://www.w3.org/2001/XMLSchema#string

P304

4872-4875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BMCL.2008.07.071

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23160564

http://www.w3.org/2001/XMLSchema#string

P698

18691886

http://www.w3.org/2001/XMLSchema#string